GTS Securities’s Quest Diagnostics DGX Stock Holding History

GTS Securities’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,270	Closed	-$220K	–	1558
2025 Q4	$220K	Buy	1,270 +97	+8%	+$17.7K	0.01%	1232
2025 Q3	$224K	Buy	+1,173	New	+$208K	0.01%	1223
2025 Q2	–	Sell	-1,481	Closed	-$251K	–	1311
2025 Q1	$251K	Buy	+1,481	New	+$243K	0.01%	1043
2024 Q4	–	Sell	-2,842	Closed	-$441K	–	1968
2024 Q3	$441K	Buy	+2,842	New	+$424K	﹤0.01%	2940
2024 Q2	–	Sell	-5,827	Closed	-$798K	–	4007
2024 Q1	$776K	Buy	5,827 +3,525	+153%	+$457K	﹤0.01%	2186
2023 Q4	$317K	Buy	+2,302	New	+$303K	﹤0.01%	3158

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

GTS Securities's DGX Position: Q1 2026 in Review

GTS Securities sold out of Quest Diagnostics (DGX) in Q1 2026, closing a stake of 1,270 shares — an estimated $220K sold.

GTS Securities first reported a position in DGX in Q4 2023 and held it in 6 quarters. The position peaked at $776K in Q1 2024. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

GTS Securities reported no remaining Quest Diagnostics position as of Q1 2026 after selling out during the quarter.
GTS Securities sold 1,270 Quest Diagnostics shares in Q1 2026, an estimated $220K.
GTS Securities first reported a position in Quest Diagnostics in Q4 2023 and held it in 6 quarters.
GTS Securities's Quest Diagnostics position peaked at $776K in Q1 2024.
1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.